Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome

Judy Nee, Katherine Salley, Andrew G Ludwig, Thomas Sommers, Sarah Ballou, Eve Takazawa, Sarah Duehren, Prashant Singh, Johanna Iturrino, Jesse Katon, Ha-Neul Lee, Vikram Rangan, Anthony J Lembo, Judy Nee, Katherine Salley, Andrew G Ludwig, Thomas Sommers, Sarah Ballou, Eve Takazawa, Sarah Duehren, Prashant Singh, Johanna Iturrino, Jesse Katon, Ha-Neul Lee, Vikram Rangan, Anthony J Lembo

Abstract

Introduction: Crofelemer, the active compound purified from latex of Croton lechleri, has been shown to improve HIV and traveler's diarrhea and improve pain in women with irritable bowel syndrome-diarrhea (IBS-D). This trial evaluated the effect of crofelemer on abdominal pain in women with IBS-D.

Methods: Women with IBS-D were randomized to crofelemer (125 mg) or placebo twice daily for 12 weeks. The primary efficacy endpoint was overall change in percentage of abdominal pain/discomfort-free days. Post hoc analysis for Food and Drug Administration (FDA) monthly responders was performed for stool consistency, abdominal pain, and combined stool consistency and abdominal pain.

Results: A total of 240 women were enrolled. There was no significant difference in overall percentage of pain/discomfort-free day between the groups. In post hoc analysis, FDA abdominal pain monthly responders were significantly more likely during months 1 through 2 (58.3% vs 45.0%, P = 0.030) as well as during the entire 3 months (54.2% vs 42.5%, P = 0.037) in the crofelemer group when compared with placebo. However, there was no significant difference in the percentage of FDA stool consistency monthly responders or combined stool consistency and pain monthly responders between the groups. Crofelemer had a safety profile similar to placebo.

Discussion: Crofelemer did not significantly improve abdominal pain over placebo by the primary endpoint. However, it did based on the FDA abdominal pain monthly responder endpoint. This suggests that crofelemer may have a role in the treatment of abdominal pain associated with IBS-D. Further studies are warranted to evaluate the potential of crofelemer as a visceral analgesic.

Trial registration: ClinicalTrials.gov NCT00461526.

Figures

Figure 1.
Figure 1.
Patient flow through the trial.
Figure 2.
Figure 2.
There were no significant differences with respect to FDA stool consistency and abdominal pain monthly responders between women in the crofelemer and placebo groups (P = 0.32, 0.28, 0.36 for months 1, 2, and 3). There were no significant differences in stool consistency monthly responders between women in the crofelemer and placebo treatment groups (P = 0.62, 0.76, 0.51 for months 1, 2, and 3). In months 1 and 3, there were no significant differences in percentage of FDA abdominal pain monthly responders between the crofelemer and placebo treatment groups (P = 0.23 for month 1 and P = 0.07 for month 3). In month 2, there were significantly more FDA abdominal pain monthly responders in the crofelemer group when compared with the placebo group. (a) There was no significant differences with respect to FDA stool consistency and abdominal pain monthly responders between the crofelemer and placebo groups (P = 0.32, 0.28, 0.36 for months 1, 2, and 3). (b) In months 1 and 3, there were no significant differences in percentage of FDA abdominal pain monthly responders between the crofelemer and placebo treatment groups (P = 0.23 for month 1 and P = 0.07 for month 3). (c) In month 2, there were significantly more abdominal pain monthly responders in the crofelemer group compared with the placebo group. FDA, Food and Drug Administration.
Figure 3.
Figure 3.
A significantly greater percentage of women in the crofelemer group were FDA abdominal pain responders during months 1, 2, and 3 when compared with the placebo group (54.2% vs 42.5%, P = 0.037). A greater percentage of women were also FDA abdominal pain responders for 2 of 3 months. By contrast, a greater percentage of women in the placebo group were FDA abdominal pain responders for 0 of 3 months and 1 of 3 months. *Indicates statistical significance. FDA, Food and Drug Administration.

References

    1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA 2015;313:949–58.
    1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol Hepatol 2012;10:712–21.e4.
    1. Mearin F, Badía X, Balboa A, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: Comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol 2001;36:1155–61.
    1. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: Systematic review and meta-analysis. Am J Gastroenterol 2012;107:991–1000.
    1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:1393–407.e5.
    1. Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes 2017;15:35.
    1. Nellesen D, Yee K, Chawla A, et al. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm 2013;19:755–64.
    1. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clin Ther 2006;28:1726–35.
    1. Hulisz D. The burden of illness of irritable bowel syndrome: Current challenges and hope for the future. J Manag Care Pharm 2004;10:299–309.
    1. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005;11:S17–26.
    1. Munjal A, Dedania B, Cash B. Update on pharmacotherapy for irritable bowel syndrome. Curr Gastroenterol Rep 2019;21:25.
    1. Fischer H, Machen TE, Widdicombe JH, et al. A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. J Ethnopharmacol 2004;93:351–7.
    1. Jones K. Review of sangre de drago (Croton lechleri)—A South American tree sap in the treatment of diarrhea, inflammation, insect bites, viral infections, and wounds: Traditional uses to clinical research. J Altern Complement Med 2003;9:877–96.
    1. Gabriel SE, Davenport SE, Steagall RJ, et al. A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion. Am J Physiol 1999;276:G58–63.
    1. Hornby PJ. Drug discovery approaches to irritable bowel syndrome. Expert Opin Drug Discov 2015;10:809–24.
    1. Irritable bowel syndrome—Clinical evaluation of drugs for treatment. Irrit Bowel Syndr 2012;17:1–17.
    1. MacArthur RD, Hawkins TN, Brown SJ, et al. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): A randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials 2013;14:261–73.
    1. DiCesare D, DuPont HL, Mathewson JJ, et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol 2002;97:2585–8.
    1. Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008;78:180–6.
    1. Lembo A, Rosenbaum D, Chey W, et al. Safety and efficacy of crofelemer in patients with diarrhea-predominant irritable bowel syndrome (D-IBS). Gastroenterology 2007;132:A141.
    1. Macdougall JE, Johnston JM, Lavins BJ, et al. An evaluation of the FDA responder endpoint for IBS-C clinical trials: Analysis of data from linaclotide phase 3 clinical trials. Neurogastroenterol Motil 2013;25:481–6.
    1. Walter SA, Kjellström L, Nyhlin H, et al. Assessment of normal bowel habits in the general adult population: The popcol study. Scand J Gastroenterol 2010;45:556–66.
    1. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016;374:242–53.
    1. Ballou S, Beath A, Kaptchuk TJ, et al. Factors associated with response to placebo in patients with irritable bowel syndrome and constipation. Clin Gastroenterol Hepatol 2018;16:1738–44.e1.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe